NCT00069706 - Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-angle Glaucoma or Ocular Hypertension Patients | Biotech Hunter

Enrollment

118

Participants

Timeline

Start Date

July 31, 2003

Primary Completion Date

October 31, 2003

Study Completion Date

October 31, 2003

Conditions

Open-angle GlaucomaOcular Hypertension

Interventions

DRUG

AL-12182 0.003% Ophthalmic Solution

Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension

OTHER

AL-12182 Ophthalmic Solution Vehicle

Placebo

DRUG

Latanoprost 0.005% Ophthalmic Solution

Commercially marketed ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension

DRUG

AL-12182 0.01% Ophthalmic Solution

Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension

DRUG

AL-12182 0.03% Ophthalmic Solution

Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension